Health Technology Assessment of Tapentadol in Palliative Oncology Patients in India
Phase 1
- Conditions
- Health Condition 1: G319- Degenerative disease of nervous system, unspecified
- Registration Number
- CTRI/2020/11/028805
- Lead Sponsor
- Indian Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 602
Inclusion Criteria
Patients above 18 years of age visiting the palliative care department
having the prescription of Morphine in either of the dosage form or
oral Tapentadol for pain management with the diagnosis of cancer of
any type.
page
Exclusion Criteria
Incomplete case records, Patients who missed a follow-up
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Specific costs and health effects will be assigned to each health state. Effects will be measured in utilities that reflected health-related quality of life. Costs will be expressed in INR and will be calculated from the perspective of the hospital. The main outcome of the analysis are costs per quality adjusted life-year (QALY) gained, expressed as incremental cost-effectiveness ratios (ICERs).Timepoint: Specific costs and health effects will be assigned to each health state. Effects will be measured in utilities that reflected health-related quality of life. Costs will be expressed in INR and will be calculated from the perspective of the hospital. The cost related of data will be collected at the time of discharge of the individual patients.
- Secondary Outcome Measures
Name Time Method To identify the impact of covariates in the direct cost of tapentadol and <br/ ><br>morphineTimepoint: End of the study